Insider buying
3 insiders in a week, 6th time since 2006Traded Nov 16 · filed 1 day later
Since the trade −2.9% · S&P 500 −6.8% · to Nov 20
Bought at the 52-week low, RSI 34, 38% under its 200-day average, 21 points behind the S&P 500 over 3 months
The CEO of Lineage Cell Therapeutics paid $37K out of pocket for Lineage Cell Therapeutics shares. 4 other people at Lineage Cell Therapeutics bought some too, in the same month. It was the first purchase in 24 months.
Lately at Lineage Cell Therapeutics: it completed buying or selling a business or assets on Nov 12; the stock is down 19% in 30 days; insiders made 5 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.